Guy Travis Clifton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guy Travis Clifton has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- George E. Peoples
Cancer Insight, San Antonio, TX
57 shared publications - Elizabeth A. Mittendorf
Dana-Farber Cancer Institute 1 Department of Medical Oncology Boston, Massachusetts
56 shared publications - Gheath Alatrash
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, USA
54 shared publications - Alexander Husband
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
53 shared publications - Anne E. O'SHea
Department of Surgery, Brooke Army Medical Center, Ft. Sam Houston, Texas
53 shared publications - Brandy M. Heckman-Stoddard
National Cancer Institute 10 Rockville, MD
53 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Supplementary Table S3: Pathologic characteristics
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Supplementary Table S3: Pathologic characteristics
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Supplementary Table S4: Lymphocyte infiltration
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Supplementary Table S4: Lymphocyte infiltration
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Supplementary Table S5: HER2 expression in biopsy and resection specimens
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Supplementary Table S5: HER2 expression in biopsy and resection specimens
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Supplementary Table S1: Demographics by therapy
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Supplementary Table S1: Demographics by therapy
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Supplementary Fig. S1: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving NeuVax with corresponding HER2 changes
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Supplementary Fig. S1: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving NeuVax with corresponding HER2 changes
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Supplementary Table S2: Median changes in percentage of nelipepimut (NPS)-specific cytotoxic lymphocytes (CTL)
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Supplementary Table S2: Median changes in percentage of nelipepimut (NPS)-specific cytotoxic lymphocytes (CTL)
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Supplementary Fig. S2: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving GM-CSF alone with corresponding HER2 changes
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Supplementary Fig. S2: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving GM-CSF alone with corresponding HER2 changes
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma in Situ
Supplementary Fig. S1: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving NeuVax with corresponding HER2 changes
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma in Situ
Supplementary Fig. S1: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving NeuVax with corresponding HER2 changes
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma in Situ
Supplementary Fig. S1: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving NeuVax with corresponding HER2 changes
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma in Situ
Supplementary Fig. S1: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving NeuVax with corresponding HER2 changes
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma in Situ
Supplementary Table S4: Lymphocyte infiltration
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma in Situ
Supplementary Table S4: Lymphocyte infiltration